Answers are grounded in this paper and cite their sources.
Demonstrates potent dual human and mouse GPBAR1 activation by novel 2-phenoxy-nicotinamides, indicating therapeutic promise for metabolic disorders.
Potency with potential: 2-Phenoxy-nicotinamides were identified as potent agonists at the GPBAR1 receptor, a target in the treatment of obesity, type 2 diabetes and metabolic syndrome. Extensive structure-activity relationship studies supported by homology modeling and docking resulted in the identification of optimized GPBAR1 agonists, potent against both human and mouse receptors, endowed with favorable physicochemical properties and good metabolic stability.
No takes yet. Share an insight, caveat, or question.
Martin et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: